Answers are grounded in this paper and cite their sources.
INTRODUCTION: Numerous viral infections necessitate immediate attention, underscoring the urgent need for effective antiviral drugs that can directly inhibit viral functions or indirectly manipulate host factors. Most direct-acting antiviral drugs target two specific viral components: polymerases (including reverse transcriptases) and proteases. Focusing on this narrow range of targets limits the scope of drug development and favors rapid resistance emergence. Therefore, targeting alternative viral components, such as viroporins, is advantageous. Viroporins constitute a family of small hydrophobic proteins encoded by viruses that oligomerize to form ion channels, thereby playing crucial roles in various stages of the viral infectivity cycle. Despite their functional significance, they have received considerably less attention from the pharmaceutical industry compared to traditional viral targets. AREA COVERED: This review delves into the significance of viral channels as potential therapeutic targets, surveying recent advancements and the prospects for future breakthroughs. Viroporins from diverse viral families and their potential inhibition by small molecules are discussed, with special emphasis on bacteria-based channel assays that facilitate high-throughput screening of channel blockers. EXPERT OPINION: Bacteria-based assays enable rapid discovery and preemptive resistance mapping, while conserved pore architectures raise the prospect of broadspectrum inhibitors. However, clinical translation requires addressing selectivity, toxicity, and pharmacokinetic challenges.
No takes yet. Share an insight, caveat, or question.
Basu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: